BNP Paribas Financial Markets Purchases Shares of 9,887 Astrana Health, Inc. (NASDAQ:ASTH)

BNP Paribas Financial Markets acquired a new position in Astrana Health, Inc. (NASDAQ:ASTH) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 9,887 shares of the company’s stock, valued at approximately $573,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. FMR LLC purchased a new stake in shares of Astrana Health during the 3rd quarter worth approximately $48,413,000. SteelPeak Wealth LLC purchased a new stake in Astrana Health during the third quarter valued at $39,398,000. Loomis Sayles & Co. L P purchased a new stake in Astrana Health during the third quarter valued at $30,251,000. NorthCrest Asset Manangement LLC purchased a new stake in shares of Astrana Health during the 3rd quarter valued at about $26,704,000. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of Astrana Health in the 3rd quarter valued at about $25,945,000. Institutional investors own 52.77% of the company’s stock.

Astrana Health Stock Down 0.3 %

Shares of NASDAQ ASTH opened at $37.63 on Friday. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60. The company’s 50-day simple moving average is $49.49 and its 200-day simple moving average is $48.03. The firm has a market cap of $2.12 billion, a price-to-earnings ratio of 28.95, a price-to-earnings-growth ratio of 1.80 and a beta of 1.13. Astrana Health, Inc. has a 52-week low of $34.11 and a 52-week high of $63.20.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. The business had revenue of $478.71 million during the quarter, compared to analysts’ expectations of $462.01 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. During the same quarter in the prior year, the company posted $0.47 EPS. Equities analysts predict that Astrana Health, Inc. will post 1.16 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ASTH. BTIG Research boosted their target price on Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, October 3rd. TD Cowen initiated coverage on shares of Astrana Health in a report on Monday, October 14th. They issued a “buy” rating and a $66.00 target price for the company. Robert W. Baird upped their price objective on Astrana Health from $67.00 to $86.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Finally, KeyCorp initiated coverage on Astrana Health in a research report on Friday, October 11th. They set a “sector weight” rating for the company. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $65.17.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.